The HCK/BTK Inhibitor KIN-8194 Is Active in MYD88 Driven Lymphomas and Overcomes Mutated BTK^Cys481 Ibrutinib Resistance

Scientists performed an extensive medicinal chemistry campaign and identified KIN-8194 as a novel dual inhibitor of HCK and BTK. KIN-8194 showed potent and selective in vitro killing of MYD88 mutated lymphoma cells, including ibrutinib resistant BTKCys481Ser expressing cells.